Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders. We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications. Precigen ActoBio™ is a wholly-owned subsidiary of Precigen. More about Precigen ActoBio: https://precigen.com/companies/precigen-actobio/ More about Precigen: https://precigen.com/ For inquiries please contact: abt.info@actobio.com
